Carfilzomib FDA Approved

FDA approved carfilzomib (Kyprolis, Onyx Pharmaceuticals, Inc., an Amgen subsidiary) in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple ymemloa who have received one to three prior lines of therapy. July 24, 2015.  More Information: Disclaimer: The EDC Developer blog is “one man’s opinion”. Anything that is said on theContinue reading “Carfilzomib FDA Approved”